Across TCGA pan-cancer cohorts, CCDC9B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CCDC9B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCDC9B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC9B expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where CCDC9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.323	0.873	.004	10	view →
LSCC	DFS	Median	II,III,IV	0.855	0.966	.020	7	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →
UCEC	OS	Median	All	0.981	0.919	.048	2	view →
HNSC	DFS	Median	IV	0.826	0.603	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: CCDC9B tumor-vs-normal RNA expression · all CCDC9B data types